Coronary Artery Disease Clinical Trial
Official title:
Evaluation of a Thin Strut Metallic Coronary Device: the Elixir DynamXTM Sirolimus Eluting Coronary Bioadaptor System
Verified date | April 2021 |
Source | Elixir Medical Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To confirm the safety and performance of the DynamX Sirolimus-eluting Coronary Bioadaptor System (SECBS) in de novo native coronary artery lesions using clinical and imaging endpoints. Clinical follow-up will be conducted in all patients at 30 days, 6 and 12 months. Imaging follow-up will be conducted at 6 months.
Status | Completed |
Enrollment | 44 |
Est. completion date | March 8, 2021 |
Est. primary completion date | March 8, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Patient must be at least 18 years of age 2. Patient is able to understand the risks, benefits and treatment alternatives of receiving the DynamX Sirolimus Eluting CBS and provide written informed consent, as approved by the NZ Ethics Committee, prior to any clinical study-related procedure 3. Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina, silent ischemia, positive functional study or electrocardiogram (ECG) changes consistent with ischemia) 4. Patient must be an acceptable candidate for coronary artery bypass graft (CABG) surgery 5. Women of childbearing potential with a negative pregnancy test within 7 days and women who are not pregnant or nursing 6. Patient must agree to undergo all clinical study required follow up visits, angiograms, and imaging testing 7. Patient must agree not to participate in any other clinical research study for a period of one year following the index procedure Angiographic inclusion criteria- Target Lesion/Vessel 8. Target lesion(s) must be located in a native coronary artery with a vessel diameter of = 2.5 and =3.5 mm assessed visually or by online QCA 9. Target lesion(s) must measure = 24 mm in length 10. Target lesion(s) must be in a major artery or branch with a visually estimated stenosis of = 50% and < 90% with a TIMI flow of = 2. When two target lesions are treated, they must be located in separate major epicardial vessels 11. The lesion(s) must be successfully pre-dilated (less than 35% DS) prior to enrollment 12. The target lesion length is 24 mm and able to be covered by a single DynamX Sirolimus Bioadaptor with 2 mm of healthy vessel on either side of planned implantation site 13. Treatment of a single, non-target lesion located in a separate major epicardial vessel Exclusion Criteria: 1. Patient has a diagnosis of ST elevation myocardial infarction (STEMI) within 72 hours preceding the index procedure, and CK and CK-MB have not returned within normal limits at the time of procedure 2. Patient requires the use of rotational atherectomy during the index procedure 3. Patient has current unstable ventricular arrhythmias 4. Patient has a known left ventricular ejection fraction (LVEF) < 30% 5. Patient has received a heart transplant or any other organ transplant or is on a waiting list for an organ transplant 6. Patient is receiving or scheduled to receive chemotherapy for malignancy within 30 days prior to or after the procedure 7. Patient is receiving immunosuppression therapy, other than steroids or has known immunosuppressive or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus etc.) 8. Patient has a known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin, clopidogrel, prasugrel or ticagrelor, Sirolimus, CoCr alloys, PLLA polymers or contrast sensitivity that cannot be adequately pre-medicated 9. Elective surgery is planned within the first 6 months after the procedure that will require discontinuing either aspirin or clopidogrel or other P2Y12 inhibitors. 10. Patient has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3, a WBC of < 3,000 cells/mm3, or documented liver disease. 11. Patient has severe renal dysfunction (CKD IV or V, eGFR <30) or is on dialysis. 12. Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions 13. Patient has had a cerebrovascular accident (CVA) or transient ischemic neurological attack (TIA) within the past six months 14. Patient has had a significant GI or urinary bleed within the past six months 15. Patient has a condition that precludes safe 6 French sheath insertion; or other medical conditions or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the clinical study plan, confound the data interpretation or associated with a limited life expectancy (i.e., less than one year) 16. Patient is already participating in another clinical study which has not reached the primary endpoint (long-term follow-up is not an exclusion) Angiographic Exclusion Criteria Target Lesion/Vessel 1. Target/Vessel / Target lesion(s) meets any of the following criteria: 1. Aorto-ostial location 2. Left main location 3. Located within 5 mm of the origin of the LAD or LCX 4. Located within an arterial or saphenous vein graft or distal to a diseased arterial or saphenous vein graft 5. Lesion involving a bifurcation with a side branch >2mm in diameter 6. Previous placement of a stent within 10 mm of the target lesion 7. Total or sub-total occlusion (TIMI flow =1) 8. The proximal target vessel or target lesion is severely calcified by visual assessment, or the lesion prevents full pre-dilatation balloon expansion 9. Previous intervention restenosis 2. The target vessel contains visible thrombus 3. Another clinically-significant lesion (>50%) is located in the same major epicardial vessel as the target lesion 5. Target vessel was previously treated with any type of PCI < 6 months prior to index procedure 6. Non-Target vessel was previously treated with any type of PCI < 30 days prior to the index procedure |
Country | Name | City | State |
---|---|---|---|
New Zealand | Auckland City Hospital | Auckland | |
New Zealand | Middlemore Hospital | Auckland | |
New Zealand | North Shore Hospital | Auckland | |
New Zealand | Christchurch Hospital | Christchurch | |
New Zealand | Dunedin Hospital | Dunedin | |
New Zealand | Waikato Hospital | Hamilton | |
New Zealand | Wellington Hospital | Wellington |
Lead Sponsor | Collaborator |
---|---|
Elixir Medical Corporation |
New Zealand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Qualitative coronary angiography | in-device late lumen loss | 6 months | |
Other | Intravascular ultrasound imaging | Change in mean lumen area from post-procedure to 6-month follow-up | 6 months | |
Primary | Target Lesion (s) Failure | composite endpoint of cardiac death, target vessel MI and clinically-indicated TLR | 6 months | |
Secondary | Target Lesion (s) Failure | composite endpoint of cardiac death, target vessel MI and clinically-indicated TLR | 1 month | |
Secondary | Target Lesion (s) Failure | composite endpoint of cardiac death, target vessel MI and clinically-indicated TLR | 12 month | |
Secondary | cardiac death | death from a cardiac cause | 1 month | |
Secondary | Cardiac Death | death from a cardiac cause | 6 months | |
Secondary | Cardiac Death | death from a cardiac cause | 12 months | |
Secondary | Non-Cardiac Death | death from a non-cardiac cause | 1 month | |
Secondary | Non-Cardiac Death | death from a non-cardiac cause | 6 months | |
Secondary | Non-Cardiac Death | death from a non-cardiac cause | 12 months | |
Secondary | myocardial infarction | all | 1 month | |
Secondary | myocardial infarction | all | 6 months | |
Secondary | myocardial infarction | all | 12 months | |
Secondary | myocardial infarction | related to the target vessel | 1 month | |
Secondary | myocardial infarction | related to the target vessel | 6 months | |
Secondary | Target Lesion Revascularization | Clinically indicated repeat intervention within the target lesion | 1 month | |
Secondary | Target Lesion Revascularization | Clinically indicated repeat intervention within the target lesion | 6 months | |
Secondary | Target Lesion Revascularization | Clinically indicated repeat intervention within the target lesion | 12 months | |
Secondary | Target Vessel Revascularization | Clinically indicated repeat intervention within the target vessel | 1 month | |
Secondary | Target Vessel Revascularization | Clinically indicated repeat intervention within the target vessel | 6 months | |
Secondary | Target Vessel Revascularization | Clinically indicated repeat intervention within the target vessel | 12 months | |
Secondary | Device Thrombosis | definite and probable as classified by an Academic Research Consortium | 1 month | |
Secondary | Device Thrombosis | definite and probable as classified by an Academic Research Consortium | 6 months | |
Secondary | Device Thrombosis | definite and probable as classified by an Academic Research Consortium | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Coronary De Novo Lesions
|
N/A |